Current guidelines recommend coronary bypass grafting (CABG) as the treatment of choice for patients with triple vessel and left main disease, although the growing use of drug-eluting stents (DES) has significantly reduced the rate of restenosis and extended the use of percutaneous coronary interventions (PCIs). Hybrid coronary revascularization (HCR) integrates the positive features of both PCI and CABG. We present preliminary results of a prospective study designed to verify the selection of candidates for treatment with hybrid approach. Between September 2011 and August 2014, 42 patients [(M ¼ 37 (88.1%); mean age 68.6 + 10.3 years, range 53-90] were selected to receive a complete (all lesions of main vessels treated) coronary revascularization with a hybrid approach at our Institution. Age-creatinine-ejection-fraction score was high (.1.277) in 16 (38%) patients, median 1.2 (0.77; 2.89). All patients underwent off-pump single-vessel revascularization (left internal thoracic artery to the left anterior descending coronary artery) using a left-anterior small thoracotomy and percutaneous coronary angioplasty. Eighteen patients (42.8%) underwent a simultaneous hybrid approach. Drug-eluting stents were used to treat 49 lesions, were also implanted 6 (7.6%) bioabsorbable stents. Procedural success was obtained in 41 (97.6%) patients. No conversion to full sternotomy and no blood transfusions were necessary during surgery. Median ventilation time was 7.7 (3-33) h and median hospital length of stay was 6 days (3-14). All patients were alive at discharge. Our early experience with HCR shows encouraging results. Randomized studies on a larger series with a longer follow-up are required.
Introduction
Surgical bypass and percutaneous coronary intervention (PCI) are traditionally considered as mutually exclusive options to be offered for revascularization of multi-vessel coronary artery disease (CAD). Each strategy is associated with advantages and disadvantages: PCI using stenting techniques can be accomplished with minimal procedural risk, facilitation of early discharge, and in the current era of drug-eluting stents (DES), a lower target vessel failure rate. 1 Although the growing use of DES has significantly reduced the rate of restenosis and extended the use of PCIs to patients with severe multi-vessel coronary disease, [2] [3] [4] [5] [6] current guidelines still recommend coronary bypass grafting (CABG) as the treatment of choice for patients with triple vessel and left main disease. Such recommendations find further support following publication of the SYNTAX trial, a landmark study conducted in a large cohort of patients with severe multivessel and/or left main disease, randomized to either CABG or PCI with a taxol-eluting stent. In keeping with earlier studies performed in patients with less severe CAD, the results of SYNTAX showed that the two strategies yield a similar 1-year survival, though PCI is associated with a greater rate of non-fatal cardiovascular events, essentially because of a greater need for new revascularizations. 1 In severe multi-vessel disease, coronary bypass surgery continues to offer a long-term prognostic advantage over PCI, largely attributable to use of the left internal mammary artery (LIMA) grafted to the left-anterior descending (LAD) artery as a durable conduit (10-year patency .90%) which provides protection against progression of disease proximal to the graft anastomosis. 4, 5 In contrast, saphenous vein graft conduits and radial artery grafts have demonstrated inconsistent short-term patency rates and limited long-term durability. 3 Hybrid coronary revascularization (HCR) integrates the positive features of both PCI and CABG, combining the durability of LIMA coronary bypass with the minimal invasiveness and lower risk of PCI. [7] [8] [9] [10] [11] [12] [13] Safety and logistical concerns of HCR have been expressed. 11 We hypothesized that in selected patients with diffuse coronary disease, a 'hybrid' approach employing a staged revascularization procedure could lower the surgical risk, increase the completeness and effectiveness of revascularization and, hopefully, improve immediate, and long-term outcome. To test this hypothesis, a well-designed, properly sized, prospective, and randomized study is needed. We report here the preliminary results of a pilot study (Figure 1 ).
Methods

Patient selection
The study population for this analysis derived from a prospective cohort of 42 patients that underwent HCR between September 2011 and August 2014. Patients with multi-vessel CAD were amenable to HCR if they fulfilled the following criteria: (i) ≥70% LAD obstruction suitable for surgical revascularization using the LIMA; (ii) patient amenable to an off-pump beating-heart revascularization procedure; (iii) non-LAD coronary lesions suitable for PCI, as adjudicated by one interventional cardiologist and one cardiac surgeon; (iv) patient's written informed consent for use of personal data.
Patients were excluded if they were haemodynamically unstable, or had acute or recent (,1 month) myocardial infarction, severe heart failure [New York Heart Association (NYHA) class IV], blood creatinine .2.2 mg/dL, allergy to radiographic contrast material, contraindication to double anti-platelet therapy for at least 12 months, previous cardiac surgery of any type, previous thoracic surgery involving the left pleural space, previous coronary stenting within the previous month for a bare-metal stent or within the previous 6 months for DES, disabling stroke within the previous 6 months, or need for concomitant cardiac surgery during index hospitalization.
Practical issues include the need for close cooperation between surgical and interventional groups, while logistical concerns include timing and sequencing of the procedures, and the use of aggressive anti-platelet therapy during the percutaneous intervention that might complicate bleeding in the surgical patient. 10 Concerning the timing and sequencing, the two procedures can be performed simultaneously, or separately as a staged procedure. For the simultaneous hybrid approach, a fluoroscopy-equipped operating room is required: we used a specially designed operating room with radiographic capability (hybrid operating suite), allowing the minimally invasive surgical LIMA grafting and PCI to be accomplished concurrently along with intraoperative angiographic assessment of the LIMA graft. 9 
Surgical technique
After intubation with a double lumen endotracheal tube, a left-anterior small thoracotomy (LAST) was performed at the 5th intercostal space through a 6-cm skin incision. The LIMA was harvested under direct vision. A minimally invasive stabilizer device was used to stabilize the target vessel (Nuvo, Medtronic, Minneapolis, MN, USA). Intra-coronary shunt was used liberally and a manual anastomosis of LIMA-LAD was performed. In one patient, standard full sternotomy and off-pump bypass were performed.
Percutaneous coronary intervention technique
Percutaneous coronary intervention was accomplished via a radial artery approach in 20 (47.6%) patients and via a femoral approach in 22 (52.3%). Guiding catheter, guidewire, and stent selection as well as pre-and post-dilation were left to the discretion of the operator. Drug-eluting stents were implanted in most patients. Bioabsorbable stents also were implanted ( Table 2) . Angiographic evaluation of vessel patency, including the surgical anastomosis, was performed in all patients. For patients who underwent the one-stage procedure, after closure of the thorax angiography was immediately performed to confirm patency of the LIMA-LAD graft and then PCI was performed on non-LAD lesions through the radial artery.
Anti-thrombotic therapy
Aspirin 100 mg/day was continued perioperatively, while clopidogrel was suspended at least 5 days before the operation. A loading dose of clopidogrel 300 mg was orally administered before PCI in the staged procedure and via a nasogastric tube after confirmation of LIMA-LAD graft patency in the simultaneous procedure, followed by 75 mg daily thereafter. Glycoprotein IIb/IIIa antagonists were not used. During PCI, unfractionated heparin was administered to obtain an activated clotting time .250 s.
Statistical analysis
Descriptive statistics [arithmetic mean, median as indicated, minimum and maximum and standard deviation (SD), 95% confidence intervals (CI) when appropriate] were calculated for continuous variables, and absolute frequencies and percentages for Hybrid coronary artery revascularization A39
by guest on March 12, 2015 qualitative variables. In calculating percentages, patients with missing data were not considered unless otherwise specified. All patients enrolled were included in the analyses. Procedural success was defined as revascularization of all eligible lesions of main vessels identified by the heart team, in the absence of complications during the index hospitalization.
Results
Between September 2011 and August 2014, 42 patients underwent HCR. For patient selection, clinical variables and coronary angiographic information were evaluated by the heart team. 14 Thirty-seven patients were male (88.1%). Mean age was 68.6 + 10.3 years (range 53-90). Age-creatinine-ejection-fraction score was high (.1.277) in 16 patients (38%), median 1.2 (0.77; 2.89) ( Table 1) .
All patients underwent off-pump single-vessel revascularization (LIMA to LAD artery) performed through a LAST procedure. After surgery, all patients underwent percutaneous revascularization of the remaining coronary targets, 18 (43%) with a simultaneous hybrid approach in a fluoroscopyequipped operating room and 24 (57%) according to a staged procedure: mean (SD) n. days from CABG: 3.29 (5.09), median (min-max) 2.00 (0.00; 30.00), 25th-75th percentile 0.00-5.00, 95% CI 1.70-4.87. All patients underwent angiographic assessment of the LIMA graft. A median of two vessels (range 1.00; 3.00) were treated. Drug-eluting stents were used in most of the lesions treated. Bioabsorbable stents also were implanted (7.6%) ( Table 2) .
No conversion to full sternotomy was necessary. Procedural success was obtained in 41 patients; in the remaining patient, the revascularization was incomplete due to unsuccessful PCI of a main vessel (circumflex artery). In six patients, small vessels were not treated, as planned. In one patient, the LIMA graft anastomosis had a severe stenosis, in the absence of symptoms and cardiac troponin release; angiography at 6 months showed an improvement of the lesion to a mild stenosis.
No blood transfusions were necessary during surgery. Postoperative blood products were used in six patients (14.3%). Median ventilation time was 7.7 (3; 33) h and median intensive care unit length of stay was 21.5 (13-158) h, as reported in Table 2 , there was a lower incidence of post-operative complications. All patients were discharged alive after a median of 7 days (4-15) showing a fast recovery. At the 12-month follow-up performed so far in 26 patients (62%), all were alive and 88.5% had returned to work.
Discussion
In hybrid revascularization, the advantage of the most durable graft (LIMA) placed to the most important vessel (LAD) is gained without a sternotomy, thereby decreasing surgical morbidity. The avoidance of aortic manipulation lowers the neurological event rate. [11] [12] [13] The use of the LIMA graft reduces the number of stents required, which may reduce the risk of thrombosis and improve long-term outcomes when compared with the use of multi-vessel stenting for full revascularization and may facilitate performance of high-risk revascularization in a single setting. 
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by guest on March 12, 2015 Both clinical variables (EuroSCORE) and angiographic information (SYNTAX score) are important in defining the risk of patients undergoing revascularization. 13 High-risk patients (e.g. those with pre-existing organ dysfunction, heavily calcified proximal aorta, depressed LV function, diabetes, unstable condition, and elderly patients) affected by multi-vessel coronary disease with a high SYNTAX score for LAD (chronic total occlusion, excessive tortuosity, diffuse calcified lesions, and unprotected left main disease) and a low score for other vessels could be the perfect candidate for hybrid revascularization, reducing the risk and combining the advantages of the two strategies. [10] [11] [12] [13] The decision to proceed with HCR should be made only after careful discussion between the surgeon, interventional cardiologist, referring cardiologist, and the patient.
14 Patients are considered eligible for HCR only if the surgeon thinks that an equivalent LIMA-LAD bypass can be performed through a minimally invasive approach and if the interventional cardiologist can perform a PCI on a non-LAD vessel with excellent technical success. 13 Relative contraindications for HCR include a nongraftable LAD, a haemodynamically unstable patient, previous sternotomy or left thoracotomy, severe pulmonary disease with inability to tolerate single-lung ventilation, body mass index .40, and non-LAD disease considered as unlikely to be successfully treated with PCI. This includes long lesions requiring multiple stents, small-diameter vessels, bifurcation lesions, chronic total occlusions, lesions previously treated with PCI, or other technically challenging lesions. 
Study limitations
The main limitation of this study is the small patients population (N ¼ 42). The intent was to be very selective in the choice of patients in order to obtain a real advantage from the hybrid procedure. Furthermore, such initial experience on hybrid procedure is performed according to predetermined conditions. The number of hybrid interventions is not related to the volume of both surgical and interventional overall procedures. In our Department, patients were selected for PCI or CABG mainly on the basis of SYNTAX trial results. The hybrid approach was considered in all patients having a multi-vessel coronaropathy with a lesion of LAD not suitable for PCI and suitable for CABG, and all other vessels treatable with PCI. For sure a study involving two-matched groups, the first receiving PCI and the second receiving CABG could be important to be able to decide the correct patients selection for hybrid procedure. We need a randomized trial that we were not in the condition to perform properly at present.
Conclusions
Our early experience with HCR shows encouraging results. Accordingly, we think that the hybrid procedure may be a valuable alternative to conventional CABG surgery in selected patients if performed in centres with adequate experience and technological capabilities appropriate for hybrid interventions. A constant interaction between cardiac surgeons and cardiologists is mandatory and surgeons should be familiar with minimally invasive surgery techniques. The involvement of an interdisciplinary team at all steps in the process-in the selection of candidates, planning, and performance of the procedure-is the key to procedural success. Randomized clinical trials are required to better define the impact of a hybrid approach on patient outcome and to determine the patient profile for whom this strategy is best suited.
